ImmuneOncia Therapeutics Inc.
5 clinical trials · Sponsor
◉ Watch ImmuneOncia Therapeutics Inc.
| Record | Firm | Date |
|---|---|---|
| A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy (NCT05276310) | ImmuneOncia Therapeutics Inc. | 2022-06-02 |
| A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type (NCT04414163) | ImmuneOncia Therapeutics Inc. | 2020-10-27 |
| A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas (NCT04306224) | ImmuneOncia Therapeutics Inc. | 2020-06-05 |
| Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors (NCT03644056) | ImmuneOncia Therapeutics Inc. | 2018-03-22 |
Track ImmuneOncia Therapeutics Inc. automatically
Every clearance here is in the API, with alerts when new ones post.